A phase II/III study of cediranib and olaparib combination compared to cediranib or olaparib alone or standard of care chemotherapy, in platinum-resistant ovarian cancer (NRG-GY005)
Jung‐Min Lee,Brady Mark,Austin Miller,Richard G. Moore,Helen Mackay,Leah McNally,Jayanthi Lea,Stéphanie Lheureux,David A. Bender,Linda Duska,Guilherme Cantuaria,Juraj Kavecansky,Charles A. Leath,Matthew A. Powell,Mark G. Cadungog,Peter G. Rose,Michael A. Bookman,Elise C. Kohn,Angeles Alvarez Secord